Vascular endothelial growth factor in colorectal cancer.
Angiogenesis plays an important role in colorectal cancer progression. Evidence from preclinical and clinical studies indicates that vascular endothelial growth factor (VEGF) is the predominant angiogenic factor in human colorectal cancer and is associated with formation of metastases and poor prognosis. Based on these results it was hypothesized that attacking one or more of the VEGF-mediated mechanisms may be promising in the treatment of colorectal cancer. AIMS. This article reviews the role of VEGF in colon cancer and summarizes recent advances in the treatment of colorectal cancer by anti-VEGF strategies.
Department of Surgery, University Clinic Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany. Markus.Guba@gch.med.uni-muenchen.de.
Markus
M
Guba
Hendrik
H
Seeliger
Axel
A
Kleespies
Karl-Walter
KW
Jauch
Christiane
C
Bruns
D000970:Antineoplastic Agents / Q000494:pharmacology; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D018450:Disease Progression; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology*; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A